TORONTO - FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A), a biopharmaceutical company, announced Monday that its subsidiary, HUGE Biopharma Australia Pty Ltd., has commenced a clinical trial to assess the safety and efficacy of its dietary supplement, unbuzzd™, in healthy volunteers experiencing alcohol intoxication.
The study, titled METAL-1 TRIAL, is a randomized, double-blind, placebo-controlled crossover trial that began on February 19, 2024.
The trial aims to provide scientific evidence to support the claim that unbuzzd™ can help individuals sober up more quickly by potentially enhancing cognition and accelerating the rate of alcohol metabolism.
The product is a fortified oral liquid formula that includes natural ingredients, vitamins, and minerals intended to replenish cofactors needed for alcohol metabolism.
FSD Pharma has granted Celly Nutrition Corp., led by industry veterans Gerry David, John Duffy, and Kevin Harrington, exclusive rights to the technology for the recreational sale and use market. Meanwhile, FSD Pharma is also focusing on developing a medical product based on the same technology for use in hospitals and by front-line workers.
CEO and co-founder of FSD Pharma, Mr. Zeeshan Saeed, expressed confidence in the potential of unbuzzd™ to change the way alcohol metabolism is managed in the body, citing a year of science-based research by the R&D team.
FSD Pharma specializes in developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Their lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation in multiple sclerosis. The company also maintains a portfolio of strategic investments secured by residential or commercial property.
The information provided in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.